mhurhangee/ep-ind-claims huggingface dataset:
A method implemented in a Power over Ethernet, PoE, system, said method comprising: receiving, by a conventional two-state electrical switch system, at least one selection of a change of state between a conductive state and a non- conductive state of the switch system; presenting, by the conventional two-state electrical switch system, each received switch system state at a state detector; converting, by the state detector, the presented at least one switch system state to a signal in a data communications network, wherein the data communications network is an Ethernet network, and wherein said converting comprises converting a conductive state of the switch system into an Ethernet loopback, and converting a non-conductive state of the switch system into an open circuit and wherein the signal is created by the presence or not of an Ethernet loopback; communicating, by the data communications network, the signal to an intelligent control device; translating, by the intelligent control device, the communicated signal to a powered device control command; transmitting, by the intelligent control device via the data communications network, the powered device control command to a powered device via a power source equipment in the data communication network; and changing, by the powered device, a state of the powered device based on the transmitted powered device control command. receiving, by a conventional two-state electrical switch system, at least one selection of a change of state between a conductive state and a non- conductive state of the switch system; presenting, by the conventional two-state electrical switch system, each received switch system state at a state detector; converting, by the state detector, the presented at least one switch system state to a signal in a data communications network, wherein the data communications network is an Ethernet network, and wherein said converting comprises converting a conductive state of the switch system into an Ethernet loopback, and converting a non-conductive state of the switch system into an open circuit and wherein the signal is created by the presence or not of an Ethernet loopback; communicating, by the data communications network, the signal to an intelligent control device; translating, by the intelligent control device, the communicated signal to a powered device control command; transmitting, by the intelligent control device via the data communications network, the powered device control command to a powered device via a power source equipment in the data communication network; and changing, by the powered device, a state of the powered device based on the transmitted powered device control command.
The reaction product of polymerizing at least one monomer, in the gas phase, in the presence of: at least one catalyst precursor produced by contacting a metal compound, wherein the metal is Zirconium or Hafnium or both, with one or more Titanium compounds selected from the group of Ti 4 where R is ethyl, isopropyl or n-butyl in the presence of an alcohol solution comprising at least one C 2 -C 4 alcohol and at least one of MgCl 2 and magnesium compounds which form MgCl 2 in the presence of the alcohol solution to form an acidity-neutral catalyst precursor solution, forming said acidity-neutral catalyst precursor solution into solid particles and subsequently halogenating the solid particles; and at least one co-catalyst.
An implantable blood pump apparatus comprising: a blood pump having a substantially tubular casing having a proximal end and a distal end and a central section extending a length therebetween, the tubular casing having a first outer diameter along at least a portion of the length, a flow path extending through the tubular casing from the proximal end to the distal end, a rotor within the flow path, a stator within the casing, and a cable housing projecting outwardly from the central section in a direction transverse to the flow path, wherein the proximal end is adapted to force, in use, native valve leaflets of a patient into an open position when positioned within a native heart valve annulus; and a pump attachment device adapted to be secured to the pump and annulus of a native valve of the patient wherein the pump attachment device is also adapted to form a seal between the exterior of the pump and the native valve. a blood pump having a substantially tubular casing having a proximal end and a distal end and a central section extending a length therebetween, the tubular casing having a first outer diameter along at least a portion of the length, a flow path extending through the tubular casing from the proximal end to the distal end, a rotor within the flow path, a stator within the casing, and a cable housing projecting outwardly from the central section in a direction transverse to the flow path, wherein the proximal end is adapted to force, in use, native valve leaflets of a patient into an open position when positioned within a native heart valve annulus; and a pump attachment device adapted to be secured to the pump and annulus of a native valve of the patient wherein the pump attachment device is also adapted to form a seal between the exterior of the pump and the native valve.
Use of L-histidine or a pharmaceutically acceptable salt thereof in the manufacture of an oral pharmaceutical composition to prevent or treat atopic dermatitis or contact dermatitis and thereby maintain and improve the barrier function of the skin; wherein the L-histidine or a pharmaceutically acceptable salt thereof is present in the composition as the only active ingredient as a powder and in a therapeutically effective amount of 2.5 to 5g.
A method comprising: contacting a metal surface with an acidic fluid comprising an aqueous base-fluid; an acid, wherein the acid comprises at least one acid selected from the group consisting of hydrochloric acid, hydrofluoric acid, an organic acid, a mineral acid, formic acid, acetic acid, citric acid, glycolic acid, hydroxyacetic acid, lactic acid, 3-hydroxypropionic acid, carbonic acid, ethylenediaminetetraacetic acid, and combinations thereof; a corrosion inhibitor, wherein the corrosion inhibitor comprises at least one compound selected from the group consisting of a cinnamaldehyde compound, an acetylenic compound, a condensation reaction product, and combinations thereof; and a corrosion inhibitor intensifier composition comprising a compound that corresponds to a formula R 1 R 2 XCCOOH, wherein: X is a halogen; R 1 comprises at least one group selected from the group consisting of a C 1 -C 20 alkyl group, a C 3 -C 20 cycloalkyl group, a C 1 -C 20 oxyalkyl, and a C 6 -C 20 aryl group; and R 2 comprises at least one group selected from the group consisting of a C 1 -C 20 alkyl group, a C 3 -C 20 cycloalkyl group, a C 1 -C 20 oxyalkyl, and a C 6 -C 20 aryl group. contacting a metal surface with an acidic fluid comprising an aqueous base-fluid; an acid, wherein the acid comprises at least one acid selected from the group consisting of hydrochloric acid, hydrofluoric acid, an organic acid, a mineral acid, formic acid, acetic acid, citric acid, glycolic acid, hydroxyacetic acid, lactic acid, 3-hydroxypropionic acid, carbonic acid, ethylenediaminetetraacetic acid, and combinations thereof; a corrosion inhibitor, wherein the corrosion inhibitor comprises at least one compound selected from the group consisting of a cinnamaldehyde compound, an acetylenic compound, a condensation reaction product, and combinations thereof; and a corrosion inhibitor intensifier composition comprising a compound that corresponds to a formula R 1 R 2 XCCOOH, wherein: X is a halogen; R 1 comprises at least one group selected from the group consisting of a C 1 -C 20 alkyl group, a C 3 -C 20 cycloalkyl group, a C 1 -C 20 oxyalkyl, and a C 6 -C 20 aryl group; and R 2 comprises at least one group selected from the group consisting of a C 1 -C 20 alkyl group, a C 3 -C 20 cycloalkyl group, a C 1 -C 20 oxyalkyl, and a C 6 -C 20 aryl group. X is a halogen; R 1 comprises at least one group selected from the group consisting of a C 1 -C 20 alkyl group, a C 3 -C 20 cycloalkyl group, a C 1 -C 20 oxyalkyl, and a C 6 -C 20 aryl group; and R 2 comprises at least one group selected from the group consisting of a C 1 -C 20 alkyl group, a C 3 -C 20 cycloalkyl group, a C 1 -C 20 oxyalkyl, and a C 6 -C 20 aryl group.
A mobile communication terminal that is adapted to operate in compliance with a wireless system, the mobile communication terminal comprising: an evaluation means that is adapted to, when not all Protocol Data Units, PDUs, that are necessary for generation of a Service Data Unit, SDU, are received, evaluate at least one of a channel type and a message type of a part of received PDUs that are necessary for generation of the SDU; and a control means that is adapted to, when the channel type or the message type evaluated by the evaluation means indicates information regarding an emergency notice, notify a user that the emergency notice is generated. an evaluation means that is adapted to, when not all Protocol Data Units, PDUs, that are necessary for generation of a Service Data Unit, SDU, are received, evaluate at least one of a channel type and a message type of a part of received PDUs that are necessary for generation of the SDU; and a control means that is adapted to, when the channel type or the message type evaluated by the evaluation means indicates information regarding an emergency notice, notify a user that the emergency notice is generated.
An optical article comprising: an ophthalmic lens comprising at least one polymerized monomer, a functional laminate comprising a thermoplastic film on each of a forward-facing surface and a rear-facing lens-contacting surface, a primer coating deposited on the lens-contacting surface of the functional laminate, wherein on the functional laminate, said primer coating comprises: at least one reactive oligomer or high molecular weight polymer with a Mw between about 2,000 and about 100,000 in an amount ranging from 1 wt.% to 25 wt.%; at least one UV or thermal initiator; at least one monomer capable of reacting with the lens polymerized monomer, wherein the monomer is present in an amount ranging from 0.25 wt.% to 15 wt.%, wherein the primer coating monomer is the same as the lens polymerized monomer or is different from the lens polymerized monomer and is, in that case, selected to include the same reactive functional group as the lens monomer, and a solvent in an amount ranging from 60 wt.% to 98.75 wt.%. an ophthalmic lens comprising at least one polymerized monomer, a functional laminate comprising a thermoplastic film on each of a forward-facing surface and a rear-facing lens-contacting surface, a primer coating deposited on the lens-contacting surface of the functional laminate, wherein on the functional laminate, said primer coating comprises: at least one reactive oligomer or high molecular weight polymer with a Mw between about 2,000 and about 100,000 in an amount ranging from 1 wt.% to 25 wt.%; at least one UV or thermal initiator; at least one monomer capable of reacting with the lens polymerized monomer, wherein the monomer is present in an amount ranging from 0.25 wt.% to 15 wt.%, wherein the primer coating monomer is the same as the lens polymerized monomer or is different from the lens polymerized monomer and is, in that case, selected to include the same reactive functional group as the lens monomer, and a solvent in an amount ranging from 60 wt.% to 98.75 wt.%. at least one reactive oligomer or high molecular weight polymer with a Mw between about 2,000 and about 100,000 in an amount ranging from 1 wt.% to 25 wt.%; at least one UV or thermal initiator; at least one monomer capable of reacting with the lens polymerized monomer, wherein the monomer is present in an amount ranging from 0.25 wt.% to 15 wt.%, wherein the primer coating monomer is the same as the lens polymerized monomer or is different from the lens polymerized monomer and is, in that case, selected to include the same reactive functional group as the lens monomer, and a solvent in an amount ranging from 60 wt.% to 98.75 wt.%.
Active agent for use in the treatment of a hair growth disorder, wherein said active agent activates, enhances, inactivates, blocks or dampens the cellular response of the taste receptor TAS2R4 or interferes with the expression of said receptor, and wherein the active agent is selected from a) any one of the TAS2R4 activating agonists amarogentin, arborescin, artemorin, azathioprine, chlorpheniramine, denatonium benzoate, diphenidol, dulcoside A, ()-epicatechin, leu-leu-leu, leu-trp, parthenolide, phe-trp, propylthiouracil, quassin, rebaudioside A, rebaudioside B, rebaudioside C, rubusoside, steviolbioside, stevioside, sucralose, taurocholic acid, trp-leu, trp-phe, trp-pro, trp-trp, trp-trp-trp, xanthoxin, yohimbine, or a combination thereof, or an aptamer binding to the TAS2R4 receptor and activating or enhancing the receptor to produce a cellular response, or b) any one of the TAS2R4 inactivating antagonists/inverse agonists carboxymethyllysine, Nα,Nα-bis(carboxymethyl)-l-lysine (BCML), glyoxal-derived lysine dimer (GOLD) and 4-(2,2,3-trimethylcyclopentyl) butanoic acid or a combination thereof, or an aptamer binding to the TAS2R4 receptor and inactivating, blocking or dampening the receptor to produce a cellular response or c) miRNA, siRNA or a ribozyme targeted to TAS2R4. a) any one of the TAS2R4 activating agonists amarogentin, arborescin, artemorin, azathioprine, chlorpheniramine, denatonium benzoate, diphenidol, dulcoside A, ()-epicatechin, leu-leu-leu, leu-trp, parthenolide, phe-trp, propylthiouracil, quassin, rebaudioside A, rebaudioside B, rebaudioside C, rubusoside, steviolbioside, stevioside, sucralose, taurocholic acid, trp-leu, trp-phe, trp-pro, trp-trp, trp-trp-trp, xanthoxin, yohimbine, or a combination thereof, or an aptamer binding to the TAS2R4 receptor and activating or enhancing the receptor to produce a cellular response, or b) any one of the TAS2R4 inactivating antagonists/inverse agonists carboxymethyllysine, Nα,Nα-bis(carboxymethyl)-l-lysine (BCML), glyoxal-derived lysine dimer (GOLD) and 4-(2,2,3-trimethylcyclopentyl) butanoic acid or a combination thereof, or an aptamer binding to the TAS2R4 receptor and inactivating, blocking or dampening the receptor to produce a cellular response or c) miRNA, siRNA or a ribozyme targeted to TAS2R4.
An inter-gear teeth error removal device for a crank pulser rotor, comprising: means (4b, 5b) detecting an angular velocity at each crank angle from an inter-crank pulse time period; means calculating, based on the angular velocity at each crank angle, a relative angular velocity at each crank angle with respect to a reference angular velocity detected in proximity of a compression top dead center of an engine; means integrating the relative angular velocity within a given crank angle range to calculate an integration angular velocity; means (9b, 11b) removing an inertia torque component and a pumping torque component from the integration angular velocity or the angular velocity before integration to calculate a post-removal integration angular velocity; means calculating and learning an inter-gear teeth error coefficient by dividing the post-removal integration angular velocity by the reference angular velocity; means calculating an inter-gear teeth error component at each engine speed using the inter-gear teeth error coefficient; and means removing the inter-gear teeth error component from the post-removal integration angular velocity. means (4b, 5b) detecting an angular velocity at each crank angle from an inter-crank pulse time period; means calculating, based on the angular velocity at each crank angle, a relative angular velocity at each crank angle with respect to a reference angular velocity detected in proximity of a compression top dead center of an engine; means integrating the relative angular velocity within a given crank angle range to calculate an integration angular velocity; means (9b, 11b) removing an inertia torque component and a pumping torque component from the integration angular velocity or the angular velocity before integration to calculate a post-removal integration angular velocity; means calculating and learning an inter-gear teeth error coefficient by dividing the post-removal integration angular velocity by the reference angular velocity; means calculating an inter-gear teeth error component at each engine speed using the inter-gear teeth error coefficient; and means removing the inter-gear teeth error component from the post-removal integration angular velocity.
An injection site for medical lines including a tubular body made of molded plastic material within which an elastic element is fitted which sealingly closes one end of said tubular body, wherein said elastic element is made of a thermoplastic material and is overmolded within the tubular body, characterized in that: - said end of the tubular body is enlarged so as to delimit an inner annular flange and is formed close to said inner annular flange with at least one radial injection through-hole through which the elastic element is overmolded, - said elastic element rests axially against said inner annular flange of the enlarged end of the tubular body and presents at least one appendage that fills said at least one radial through-hole. - said end of the tubular body is enlarged so as to delimit an inner annular flange and is formed close to said inner annular flange with at least one radial injection through-hole through which the elastic element is overmolded, - said elastic element rests axially against said inner annular flange of the enlarged end of the tubular body and presents at least one appendage that fills said at least one radial through-hole.
Non-crystalline aspirin, obtainable by a process comprising applying laser radiation from at least two different lasers to a solution of aspirin in a solvent, and evaporating the solvent, wherein the laser radiation is optionally pulsed, having pulses with an effective average pulse length of no more than 10 -9 seconds, and the laser radiation from each laser is of a different wavelength, and wherein the non-crystalline aspirin does not crystallize during storage for at least 30 days at a temperature of from 20° to 30°C.
An electromagnetic field control member for charged particle accelerators comprising an insulating member made of a ceramic having a tubular shape, the insulating member comprising a plurality of through holes extending in an axial direction; a conductive member made of a metal, the conductive member sealing off each through hole of the plurality of through holes and leaving an opening portion in the through hole, the opening portion opening to an outer periphery of the insulating member; and a power feed terminal (5,6) connected to the conductive member, wherein each through hole of the plurality of through holes comprises inner wall surfaces, the inner wall surfaces further comprising: inclined surfaces for which a width between inner walls of the inclined surfaces facing each other gradually increases from an inner periphery of the insulating member to the outer periphery of the insulating member; and vertical surfaces located on an inner peripheral side of the insulating member and for which a width between inner walls of the vertical surfaces facing each other is constant, wherein the conductive member is disposed at a site in each through hole where the vertical surfaces are located, and seals off the through hole. an insulating member made of a ceramic having a tubular shape, the insulating member comprising a plurality of through holes extending in an axial direction; a conductive member made of a metal, the conductive member sealing off each through hole of the plurality of through holes and leaving an opening portion in the through hole, the opening portion opening to an outer periphery of the insulating member; and a power feed terminal (5,6) connected to the conductive member, wherein each through hole of the plurality of through holes comprises inner wall surfaces, the inner wall surfaces further comprising: inclined surfaces for which a width between inner walls of the inclined surfaces facing each other gradually increases from an inner periphery of the insulating member to the outer periphery of the insulating member; and vertical surfaces located on an inner peripheral side of the insulating member and for which a width between inner walls of the vertical surfaces facing each other is constant, wherein the conductive member is disposed at a site in each through hole where the vertical surfaces are located, and seals off the through hole.
A compound, represented by Formulae 6, 10 and 14 to 16 below: wherein R1 and R2 are each independently alkoxy of C5 ~ C15 unsubstituted or substituted with alkyl of C1 ~ C 15; m is an integer of 0 ~ 5. wherein R1 and R2 are each independently alkoxy of C5 ~ C15 unsubstituted or substituted with alkyl of C1 ~ C 15; m is an integer of 0 ~ 5.
A composition for use in treating a progesterone-dependent condition selected from the group consisting of endometriosis and pain associated therewith, adenomyosis, endometriomas of the ovary, dysmenorrhea, uterine fibroids, endometrial hyperproliferation, ovarian cancer, and cervical cancer in a female in need thereof wherein the use comprises: (a) the use of said composition comprising a selective progesterone receptor modulator (SPRM) selected from CDB-4124 (21-methoxy-17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dione) and 17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dione wherein the administration is oral for a period beginning on day 16 to 28 of a first menstrual cycle and ending on day 11-25 of a subsequent second menstrual cycle; and (b) contemporaneously the use of said composition comprising an SPRM selected from CDB-4124 and 17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dione wherein the administration is vaginal for period beginning on day 1-10 of the second menstrual cycle and wherein the vaginal administrations of said composition is continued until a desired therapeutic effect is achieved. (a) the use of said composition comprising a selective progesterone receptor modulator (SPRM) selected from CDB-4124 (21-methoxy-17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dione) and 17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dione wherein the administration is oral for a period beginning on day 16 to 28 of a first menstrual cycle and ending on day 11-25 of a subsequent second menstrual cycle; and (b) contemporaneously the use of said composition comprising an SPRM selected from CDB-4124 and 17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dione wherein the administration is vaginal for period beginning on day 1-10 of the second menstrual cycle and wherein the vaginal administrations of said composition is continued until a desired therapeutic effect is achieved.